Drug Profile
Research programme: macrophage metalloelastase inhibitors - Novartis
Alternative Names: Macrophage metalloelastase inhibitors research programme - Novartis; MME inhibitors research programme - Novartis; Research programme: MME inhibitors - NovartisLatest Information Update: 14 Aug 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Emphysema
Most Recent Events
- 14 Aug 2001 No-Development-Reported for Emphysema in USA (Unknown route)
- 13 Aug 1998 New profile
- 13 Aug 1998 Preclinical development for Emphysema in USA (Unknown route)